

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 9/26, 9 /24, 31 /557 // (A61K 31 /557, 31 :195)</b>		A1	(11) International Publication Number: <b>WO 00/01368</b>
			(43) International Publication Date: 13 January 2000 (13.01.00)
(21) International Application Number: PCT/GB99/01951		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 30 June 1999 (30.06.99)		<b>Published</b> <i>With international search report.</i>	
(30) Priority Data: 9814215.1 1 July 1998 (01.07.98) GB			
(71) Applicant (for all designated States except US): NORTON HEALTHCARE LTD. [GB/GB]; Albert Basin, Royal Docks, London E16 2QJ (GB).			
(72) Inventor; and (75) Inventor/Applicant (for US only): WOOLFE, Austin, John [GB/GB]; 31 Emberson Way, North Weald, Essex CM19 6DL (GB).			
(74) Agent: BROWNE, Robin, Forsythe; Urquhart-Dykes & Lord, Tower House, Merrion Way, Leeds LS2 8PA (GB).			
(54) Title: ANTI-INFLAMMATORY PHARMACEUTICAL FORMULATIONS			
(57) Abstract			
A pharmaceutical dosage form comprising a tablet containing a non-steroidal anti-inflammatory drug and misoprostol, wherein the non-steroidal anti-inflammatory drug is in the form of coated pellets.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ANTI-INFLAMMATORY PHARMACEUTICAL FORMULATIONS

This invention relates to pharmaceutical formulations of anti-inflammatory drugs, particularly non-steroid and anti-inflammatory drugs (NSAIDs).

These NSAIDs are used for the treatment of inflammatory conditions such as osteoarthritis or rheumatoid arthritis. A side effect of the oral administration of NSAIDs particularly with long term usage, is a liability to ulcerogenic effects. NSAID induced ulcers in the stomach are potentially dangerous because few or no symptoms may be detected until significant damage has been caused. Certain prostoglandins, for example misoprostol have been shown to reduce and even prevent such ulcers.

It has been found experimentally that it is necessary for the prostaglandin to be released before the NSAID so as to protect the stomach from the effects of the NSAID. It is therefore preferable that the NSAID is coated to delay release. The coating may be a standard hydroxypropyl methyl cellulose coat of a thickness sufficient to delay release in the stomach for a short period, an enteric coat to delay NSAID release until it reaches the intestine, or a delay release coating to allow drug release over a period of time to permit less frequent dosing.

In addition the coating may act as a barrier between the NSAID and the prostaglandin to prevent decomposition of the prostaglandin caused by instability in the presence of the NSAID.

EP-527887B discloses a pharmaceutical composition comprising a core of an NSAID surrounded by a coating containing the prostaglandin. The core is preferably coated

-2-

with a barrier of enteric coat before a mantle coat is added. No experimental details are given. It appears that this dosage form is made by press-coating, ie a tablet core containing the drug is made, and coated before being put in a second tableting operation to cover the coated core. Such a procedure requires use of specialised equipment which is not a normal pharmaceutical production tool and hence would need significant investment.

According to the present invention an oral pharmaceutical dosage form comprises a tablet containing a non-asteroidal anti inflammatory drug and misoprostol, wherein the non-asteroidal anti inflammatory drug is in the form of coated pellets.

The NSAID is preferably but not exclusively one of reasonably low weight per standard dose. That is an NSAID where the usual dose is 200 mg or below. Examples of such NSAIDs include indomethacin, piroxicam, meloxicam, flubiprofen, naproxan, ketoprofen, tenoxicam or similar molecules. Most preferably the drug is diclofenac sodium.

Enteric coated or delay release coated pellets have not been widely used because many workers have found damage or cracking to the enteric or delay release coating during the tablet compression stage. The present invention will work most effectively if the coating remains intact during compression.

It is possible to produce such pellets by conventional means although care is needed to ensure coat cracking does not occur. Techniques which can be used include coating the drug on a non-pariel core preferably composed of inert sugar or similar substance and then overcoating with the required coating before compression.

A preferred method is to form pellets by co-acervation or alternatively by precipitation of the pellets from solution as described by Zaruboru, Fell and Collett, (Int.J.Pharm, 1995, 125, 151-5).

In another preferred technique the pellets may be formed by spheronisation, rotogranulation or a similar technique. Preferably the pellets should be soft enough to deform slightly under compression to avoid cracking but not too soft so as to deform significantly which will also cause cracking or rupture of the coat. A suitable mixture of drug with a suitable amount of an excipient or several excipients can be found by simple, routine experiments. Suitable excipients include polyvinyl pyrrolidone, sugars and cellulose derivatives particularly microcrystalline cellulose. A coating for the pellets may employ cellulose derivatives eg hydroxypropyl methyl cellulose, methacrylic acid and derivatives eg methyl methacrylates for example, Eudragrit® (Rhom Pharma), especially Eudragrit L or S. Other standard enteric coating materials for example phthalates, eg cellulose acetate phthalate or preferably hydroxypropylacetate phthalate or polyvinylacetate phthalate. Mixtures of these and other materials may be used to produce delay release coated beads. Normally coating will include plasticisers eg polyethylene glycol, triacilin or phthalate esters.

It has been found in practice that smaller pellets are better for use in accordance with this invention, preferably between 0.25 mm to 1.5 mm in diameter. Most preferably pellets between 0.8 mm to 1.2 mm diameter are employed. Pellets of this diameter show less tendency to crack under the compression forces.

The external compression material will include a prostaglandin, preferably misoprostol together with inert excipients. The prostaglandin may be used neat or it may be preferably diluted on an inert material. A preferred material is misoprostol diluted on hydroxypropyl methyl cellulose or polyvinyl pyrrolidone. Other diluents may be used. The other materials which may be employed include inert fillers, binders, lubricants and colorants as used in normal pharmaceutical tablet making. An especially useful material for this invention is microcrystalline cellulose. The dosage of prostaglandin will be chosen to be suitable to prevent or reduce stomach ulceration caused by the NSAID. A suitable dose of misoprostol is between 100 - 200 micrograms per tablet but this may be increased or decreased depending on the NSAID used.

The coated pellets and prostaglandin mixture are then compressed on conventional tableting equipment. Tablets may have a break line or break lines to facilitate smaller doses. The tablet may be film or sugar coated if required.

Bilayer tablets may be employed. The non-steroidal anti inflammatory drug and excipients may be compressed into the lower half of the tablet and the misoprostol together with excipients superimposed and pressed onto it. A barrier layer may be provided between the two active ingredient-containing layers. The misoprostol containing layer may incorporate excipients to facilitate rapid dissolution of this active ingredient.

The invention is further described by means of example but not in any limitative sense.

-5-

EXPERIMENT 1

The following ingredients were employed.

Diclofenac Pellets Enteric Coated 40%	123 mg
Misoprostol Dispersion on HPMC (1:100)	20 mg
1) Microcrystalline Cellulose (Avicel 102)	33 mg
2) Sodium Starch Glycollate	3 mg
3) Hydrogenated Cottonseed Oil	1 mg

The excipients 1 + 2 and misoprostol were sieved through a 250  $\mu$ m screen. The diclofenac pellets were added and blended for 15 min in a cube blender. The lubricant 3) was added and the mixture was reblended for 5 min and compressed at 180 mg/tablet.

EXPERIMENT 2

The mixture from Experiment 1 was blended with the equivalent of another 100 mg of microcrystalline cellulose and was then compressed at 280 mg/tablet.

EXPERIMENT 3

The following ingredients were employed.

Mix 1	Diclofenac Pellets Enteric Coated 40%	123 mg
	Microcrystalline Cellulose	133 mg
	Sodium Starch Glycollate	3 mg
	Hydrogenated Cottonseed Oil	1 mg

-6-

Mix 2	Misoprostol dilution (1:100)	20 mg
	Microcrystalline Cellulose	196 mg
	Sodium Starch Glycollate	3 mg
	Hydrogenated Cottonseed Oil	1 mg

Mixture 1 was prepared with sieved excipients and then compressed to form a layer, having a weight of 260 mg.

Mixture 2 was prepared and compressed on top of the diclofenac layer to atop weight of 120 mg, ie total 360 mg.

The resulting bilayer tablets were overcoated with an HPMC taste masking coat. The bead diameter was 1.05 to 1.16 mm.

#### Results.

Experiment 1 using USP baskets

Dissolution in acid 0.1 MHCL for 2 hrs

Less than 4% release.

Dissolution in pH 6.8 buffer

98-106% release after 1 hr

Scanning Electronic Microscopy showed no breakage of the enteric coating of the pellets after compression.



## CLAIMS

1. A pharmaceutical dosage form comprising a tablet containing a non-steroidal anti inflammatory drug and misoprostol, wherein the non-steroidal anti inflammatory drug is in the form of coated pellets.
2. A dosage form as claimed in claim 1 containing a uniform mixture of coated non-steroidal anti inflammatory pellets and misoprostol.
3. A dosage form as claimed in claim 1 comprising a bilayer tablet containing coated non-steroidal anti inflammatory pellets in one layer and misoprostol in a second layer.
4. A dosage form as claimed in any preceding claim wherein the pellets include an overcoating of a barrier layer upon a pellet including a layer of non-steroidal anti inflammatory drugs sprayed or otherwise coated on a non-parietal core.
5. A dosage form as claimed in any preceding claim wherein the coating is an enteric coating.
6. A dosage form as claimed in claim 5 wherein the enteric coating is selected from: a methylmethacrylate copolymer, a polyvinylacetate phthalate, cellulose acetate phthalate, or hydroxypropylmethyl cellulose phthalate.

-8-

7. A dosage form as claimed in claim 6 wherein the enteric coat includes a plasticiser.
8. A dosage form as claimed in any of claims 5 to 7 including a barrier inert coat disposed between the drug core and the enteric coating.
9. A dosage form as claimed in claim 7 wherein the barrier coat is a cellulose derivative.
10. A dosage form as claimed in any of claims 1 to 4 wherein the pellets are coated with a barrier coat adapted to delay release of the non-steroidal anti inflammatory drug.
11. A dosage form as claimed in any of claims 1 to 4 wherein the pellets are coated with a delay release coat adapted to release the drug throughout the gastrointestinal tract.
12. A dosage form as claimed in claim 11 wherein the delay release coat is formed from a methacrylate polymer or a mixture of a methacrylate polymer and a cellulose derivative.
13. A dosage form as claimed in any preceding claim wherein the pellets have a diameter of 0.25 to 1.5 mm.
14. A dosage form as claimed in claim 13 wherein the pellets have a diameter of 0.8 to 1.2 mm.

-9-

15. A dosage form as claimed in any preceding claim including one or more excipients selected from binders, lubricants, colorants, bulking agents and disintegrants.
16. A dosage form as claimed in any preceding claim wherein the non-steroidal anti inflammatory drug is diclofenac.
17. A dosage form as claimed in any of claims 1 to 15 wherein the non-steroidal anti inflammatory drug is ketoprofen.
18. A dosage form as claimed in any of claims 1 to 15 wherein the non-steroidal anti inflammatory drug is naproxen.
19. A dosage form as claimed in any of claims 1 to 15 wherein the non-steroidal anti inflammatory drug is selected from piroxicam and meloxicam.
20. A dosage form as claimed in any preceding claim comprising a tablet overcoated with a sugar or cellulose film barrier coating.
21. A dosage form as claimed in any preceding claim comprising a tablet overcoated with a barrier or taste masking coating.
22. A dosage form as claimed in any preceding claim comprising a tablet wherein the ratio of diclofenac to

-10-

excipients either in the whole tablet or in the diclofenac layer is between 70:30 and 30:70 parts by weight.

23. A method of manufacture of a pharmaceutical dosage form as claimed in claim 1 wherein the pellets are formed by extrusion and spheronisation of a mixture containing a non-steroidal anti inflammatory drug, followed by coating with a barrier coat.

24. A method of manufacture of a dosage form as claimed in claim 1 wherein the pellets are made by coasservation or precipitation from solution.

25. A method as claimed in claim 24 wherein an enteric coat is formed by contacting solutions of an alkali salt of a non-steroidal anti inflammatory drug, and enteric form forming polymer and an acid.

26. A method as claimed in claim 24 or 25 wherein the misoprostol is absorbed onto hydroxypropylmethylcellulose or other cellulose derivative prior to incorporation into a tablet.

27. A method of manufacture of a pharmaceutical tablet comprising the steps of mixing a coated pellet containing a non-steroidal anti inflammatory drug together with a powder containing misoprostol absorbed on a cellulose, polyvinylchloride or other excipient optionally together with one or more binding agents, bulking agents, disintegrants and lubricants and compressing the mixture to form tablets.

28. A method of manufacture of a pharmaceutical bilayer tablet consisting of mixing coated pellets containing a non-steroidal anti inflammatory drug with optional excipients selected from binders, bulking agents, disintegrants and lubricants; compressing the mixture to form the bottom half of a tablet and superimposing a mixture of misoprostol absorbed on a cellulose or polyvinylchloride or other material together with or more optional excipients selected from binders, bulking agents, disintegrants and lubricants; to form a tablet suitable for human administration.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01951

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/26 A61K9/24 A61K31/557 //(A61K31/557,31:195)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91 16895 A (G.D. SEARLE & CO.) 14 November 1991 (1991-11-14) the whole document & EP 0 527 887 A cited in the application ---	1-28
Y	US 3 488 418 A (HOLLIDAY ET AL.) 6 January 1970 (1970-01-06) column 8, line 53 -column 9, line 19 ---	1-28
Y	EP 0 196 546 A (ABBOTT LABORATORIES) 8 October 1986 (1986-10-08) page 4 -page 5; example 1 ---	1-28
Y	WO 98 20870 A (POZEN, INC.) 22 May 1998 (1998-05-22) page 38 -page 40; example 1 -----	1-28

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*S\* document member of the same patent family

Date of the actual completion of the international search

14 October 1999

Date of mailing of the international search report

21/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PC./GB 99/01951

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9116895 A	14-11-1991	AT 121625 T AU 7876491 A CA 2082944 A,C DE 69109286 D DE 69109286 T DK 527887 T EP 0527887 A ES 2071312 T GR 3015939 T IE 68596 B IL 98033 A PT 97562 A,B US 5601843 A US 5698225 A	15-05-1995 27-11-1991 04-11-1991 01-06-1995 28-09-1995 03-07-1995 24-02-1993 16-06-1995 31-07-1995 26-06-1996 31-07-1995 28-02-1992 11-02-1997 16-12-1997
US 3488418 A	06-01-1970	DE 1617374 A FR 5788 M GB 1116438 A IT 1193741 B US 3524910 A	01-04-1971 18-03-1968  24-08-1988 18-08-1970
EP 196546 A	08-10-1986	CA 1259924 A DE 3683664 A JP 61221115 A US 4874614 A	26-09-1989 12-03-1992 01-10-1986 17-10-1989
WO 9820870 A	22-05-1998	AU 5201098 A	03-06-1998